APP and Alzheimer disease: The number of GFAP+ cells in the mouse brain was calculated, and compared to that in APP/PS1 mice, the number of GFAP+ cells in WT and AD mice treated with P2Y1-shRNA was decreased (Fig. 5, D and E).